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Background: There are limited population-based studies focusing on the chemopreventive effects of selective
cyclooxygenase-2 (COX-2) inhibitors against colorectal cancer. The purpose of this study is to assess the trends and
dose–response effects of various medication possession ratios (MPR) of selective COX-2 inhibitor used for
chemoprevention of colorectal cancer.
Methods: A population-based case–control study was conducted using the Taiwan Health Insurance Research
Database (NHIRD). The study comprised 21,460 colorectal cancer patients and 79,331 controls. The conditional
logistic regression was applied to estimate the odds ratios (ORs) for COX-2 inhibitors used for several durations
(5 years, 3 years, 1 year, 6 months and 3 months) prior to the index date.
Results: In patients receiving selective COX-2 inhibitors, the OR was 0.51 (95% CI=0.29~0.90, p=0.021) for an
estimated 5-year period in developing colorectal cancer. ORs showing significant protection effects were found in
10% of MPRs for 5-year, 3-year, and 1-year usage. Risk reduction against colorectal cancer by selective COX-2
inhibitors was observed as early as 6 months after usage.
Conclusion: Our results indicate that selective COX-2 inhibitors may reduce the development of colorectal cancer
by at least 10% based on the MPRs evaluated. Given the limited number of clinical reports from general
populations, our results add to the knowledge of chemopreventive effects of selective COX-2 inhibitors against
cancer in individuals at no increased risk of colorectal cancer.
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Colorectal cancer (CRC) is currently a common cancer
in many countries [1]. In Taiwan it is the second leading
cause of cancer-related death, with a 5-year survival rate
of 56% and a median age of 68 years [2]. The incidence
of CRC is a global health problem, and the search for
chemopreventive agents to inhibit its carcinogenesis is
urgently required.
Cyclooxygenase-2 (COX-2) has been found to be over-
expressed in a number of cancers, including CRC, and
has been shown to stimulate tumorigenic pathways [3,4].
Therefore, COX-2 is a valid target for inhibiting or* Correspondence: yhkao@mail.ncku.edu.tw
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reproduction in any medium, provided the orpreventing carcinogenesis [3,5]. Non-steroidal anti-
inflammatory drugs (NSAIDs) inhibit both isoforms of
cyclooxygenase (COX-1 and COX-2). In the gastrointes-
tinal tract, COX-1 produces prostanoids that are
involved in the defense and repair of the gastrointestinal
mucosa, while COX-2 is expressed in response to in-
flammatory stimulation [3]. Variation in the chemical
structure of existing NSAIDs results in different
specificities for COX-1 and COX-2 [6]. Traditional
NSAIDs, such as aspirin, are generally less selective for
COX-2, whereas Coxibs (celecoxib, rofecoxib) have
higher COX-2 selectivity. Given the different roles of
COX enzymes in the gastrointestinal tract, selective
COX-2 inhibitors have been shown to have less gastro-
intestinal toxicity than traditional NSAIDs [4].d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Yang et al. BMC Cancer 2012, 12:582 Page 2 of 10
http://www.biomedcentral.com/1471-2407/12/582Most clinical studies investigating the chemopreven-
tive role of selective COX-2 inhibitors have been con-
ducted in Western populations [7]. Therefore, it is of
interest to conduct similar population-based studies in
an Asian population so that comparisons among demo-
graphic groups can be made. The Taiwan Health Insur-
ance Research Database (NHIRD) contains all health
insurance claims made in the Taiwanese population,
serving as a useful resource to conduct this type of
population-based study.
The purpose of this study is to assess the trends and
dose–response effects of various medication possession
ratios (MPR) for selective COX-2 inhibitor usage in che-
moprevention of CRC. Furthermore, subgroups of gen-
der and age categories are compared.
Methods
Data source
The National Health Insurance (NHI) program was
initiated in 1995 and covers all medical services in Taiwan.
The coverage of the NHI program was initially 93.1% of
the entire Taiwanese population in 1996, rising to 99.6%
by 2010. The program’s National Health Insurance Re-
search Database (NHIRD) contains inpatient and out-
patient medical and prescription drug claims as well as
the demographic data of all beneficiaries. We used two
sets of data from the NHIRD in this study to construct
our case and control groups. This ethics of using the data-
base and the study design was reviewed and approved by
the Institutional Review Board of Kaohsiung Medical Uni-
versity Hospital (KMUH-IRB-980174).
Case group
We retrieved an 11-year longitudinal database (1997–
2007) of patients who have at least one diagnosis of ICD
9 (International Classification of Diseases revision 9 code
140–208) from the NHIRD. This database includes
records of inpatients, outpatients and pharmaceuticals.
As these patients were reported in the NHI database for
cancer screening purposes, the actual CRC patients could
be identified by linking their encrypted personal identifi-
cation number to the Registry for Catastrophic Illness
patients with ICD 9 code 153–154. The date of first diag-
nosis was considered the index date for each patient.
For the period 2002–2006, we identified 42,358 CRC
patients from the database. For the same period, the
number of cancer cases reported by the Taiwan Cancer
Registry was 46,432 across all ages [2]. Thus, the patients
we identified accounted for 91% of the total Cancer
Registry patients. We excluded patients whose age was
not between 18 and 100 years old or who were diag-
nosed with other cancers (ICD 9 code 140–208, except
153–154) or benign lesions (ICD 9 code 210–239) prior
to the index date.Control
We selected controls from the Longitudinal Health In-
surance Database 2005 (LHID2005, years 1996–2006).
The LHID2005 contains all the original claims of
1,000,000 beneficiaries, randomly sampled from the
Registry for Beneficiaries (ID) of the NHI database in
2005. According to the NHIRD report, there was no sig-
nificant demographical difference between the patients
in the LHID2005 and the whole National Health Insur-
ance database. At most, 10 randomly selected controls,
without any history of cancer (ICD9 code 140–208) or
benign neoplasm (ICD9 code 210–239), were matched
with each CRC patient in terms of gender and birth year.
The index date of each CRC patient was assigned as the
index date to each of the matched controls.
Drug categories and dosage
The selectivity of a given NSAID can be expressed by
the COX-1/COX-2 IC50 ratio. Drugs which are more se-
lective for COX-2, such as coxibs, have lower IC50 ratios
than traditional NSAIDs [8]. Selective COX-2 inhibitors
(celecoxib and rofecoxib) became eligible for reimburse-
ment by the NHI program starting in 2001. Rofecoxib
was withdrawn from the market in 2004, therefore cele-
coxib is the only currently recorded selective COX-2 in-
hibitor in the NHIRD. In addition to selective COX-2
inhibitors, we used data from patients using traditional
NSAIDs (indomethacin, sulindac, diclofenac, acemeta-
cin, ketorolac, piroxicam, ibuprofen, naproxen, ketopro-
fen and mefenamic acid) and preferential COX-2
inhibitors (nabumetone, meloxicam, etodolac and nime-
sulide) as covariates in statistical analyses.
We determined patient usage of the three prescribed
drug types (selective COX-2 inhibitors, traditional
NSAIDs and preferential COX-2 inhibitors) from data
obtained by the Details of Inpatient Orders (DO) and
Details of Ambulatory Care Orders (OO) from the Ori-
ginal Claim Database. Information obtained included de-
livery dates, number of tablets, capsules or other
dispensation vehicles, drug dosage, and duration of the
prescription period. We used all prescriptions of oral
traditional NSAIDs, selective COX-2 inhibitors and pre-
ferential COX-2 inhibitors filled during the follow-up
period as independent variables in our statistical ana-
lyses. The defined daily dosage (DDD), which is the aver-
age dosage of a drug taken by adults for the most
frequent indication, was computed according to the ana-
tomic therapeutic chemical (ATC) classification system
from WHO [9].
Follow-up groups
We created three follow-up groups of different durations
(all beginning in 1997) to ensure each patient had the
same observation period, and to maximize the number
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had patients with full 5-year observation records before
their index date, and hence, only cancer patients with
their first diagnosis between 2002 and 2006 were
included (Figure 1). Similarly, for the 3-year and 1-year
follow-up groups, cancer patients with their first diagno-
sis between 2000 and 2006 and between 1998 and 2006,
respectively, were included. We used the 1-year follow-
up group to obtain data regarding patients that used the
drugs for 3 and 6 months.
Statistical analysis
Each CRC patient and the corresponding matched con-
trols were considered as a stratum in the matched case–
control study. During variable analysis between cases
and controls, each case was matched with 10 controls.
We used the reciprocals of the values in the control
group and applied them as weights in the estimates and
hypothesis testing.
We used conditional logistic regression to determine
the estimated drug effects, as determined by their odds
ratios (ORs) and 95% confidence intervals (CI), of select-
ive COX-2 inhibitors used over different durations
(5 years, 3 years, 1 year, 6 months and 3 months). The
medication possession ratios (MPRs) of the inhibitors,
calculated by dividing the cumulative DDD by the total
number of days in each follow-up period, were used as a
continuous independent variable.
The MPRs of selective COX-2 inhibitors were ordered
in increments of 10% with 10% and 90% as cut-off
points. For subjects with an MPR of 10%, 50%, or 90%,
we generated three categorical variables for each: sub-
jects taking the drug for at least 50% of their follow-up
period; subjects taking the drug for less than 50% of thepuorg lortnoCpuorg esaC
Database of patients with








cancer patients aged 18-




free of diagnosis for
cancers and benign
lesions
21460 colon cancer patients and 79331 controls
matched with gender and birth year
Case-control study
Figure 1 Flowchart of data acquisition.time; and non-users (the reference group). In total, nine
separate conditional logistic models were generated for
these three MPRs.
In addition to the variables calculated for selective
COX-2 inhibitors, we added the following covariates
into the conditional logistic regression analysis models:
1) MPRs of traditional NSAIDs and preferential COX-2
inhibitors; 2) three categories of insured payroll claims;
3) five different residential areas; and 4) comorbidities
with dichotomous variables for 15 medical conditions.
We used the ICD 9 codes specified in the Charlson
comorbidity index [10,11] for the 15 diseases were used
to define diseases that were present within the same dur-
ation of cumulative DDD before the index dates. Any
recorded diagnosis in inpatient or outpatient records
would be considered as having diseases.
Sensitivity analysis
Sensitivity analyses were conducted in this study with a
series of 5-, 3- and 1-year follow-up groups. The use of
selective COX-2 inhibitors can have various side effects,
including congestive heart failure or cardiovascular dis-
orders. We also conducted separate analyses on partici-
pants without any occurrence of myocardial infarction
or congestive heart failure, without any occurrence of
peptic ulcer disease, and without any occurrence
of colon or rectal polyps. For patients with occurrence
of diseases, only patients with peptic ulcer disease had
sufficient sample size for conditional logistic regressions.
Results
The study database of the 5-year follow-up group com-
prised 21,460 cases and 79,331 controls. The basic char-
acteristics for the 5-year follow-up groups are shown in
Table 1. At the index dates, the average (±sd, standard
deviation) age of subjects in the group of 65–100 year
olds was 75.20 (±6.67) years, and in the group of 18–64
year olds it was 52.45 (±9.21) years. Characteristics
regarding basic information and potential confounding
variables are given in Table 1. For prevalence rates of
comorbidity, the prior 5-year prevalence rates of con-
gestive heart failure (8.7% vs. 7.5%), peptic ulcer disease
(37.2% vs. 27.6%), mild liver disease (19.1% vs. 15.5%),
diabetes (22.6% vs. 19.0%) and renal disease (8.5% vs.
7.2%) were significantly higher in the CRC group, and
the prevalence of dementia was higher in the control
group. The proportions of having at least one prescrip-
tion in the prior 5 years for selective COX-2 inhibitors
were not significantly different (p=0.595); however,
the average cumulative defined daily dose (DDD) dif-
fered significantly between CRC patients and controls
(78.0±151.1 vs. 85.5±120.5, p=0.010).
The estimated effects (odds ratios, ORs) of drug usages
in various durations (5-year, 3-year, 1 year, 6 months and
Table 1 Basic characteristics among patients and controls
Cancer patients Controls
Variable Item n % na %a p-value
total 21460 79331
sex
male 12882 60.0 47621 60.0
female 8578 40.0 31710 40.0
age group
18-64 years old 9072 42.3 33536 42.3
65-100 years old 12388 57.7 45795 57.7
income category
not working 6958 32.4 23361 29.4 <.001
monthly income<= NT$20000 11019 51.3 45805 57.7
monthly income> NT$20000 3483 16.2 10165 12.8
comorbidity in 5 years before index date
Myocardial infarction 486 2.3 1784 2.2 0.888
Congestive heart failure 1864 8.7 5917 7.5 <.001
Peripheral vascular disease 609 2.8 2315 2.9 0.534
Cerebrovascular disease 3724 17.4 13514 17.0 0.273
Dementia 655 3.1 2825 3.6 <.001
Chronic pulmonary disease 7002 32.6 25707 32.4 0.534
Rheumatologic disease 692 3.2 2552 3.2 0.957
Peptic ulcer disease 7974 37.2 21875 27.6 <.001
Mild liver disease 4092 19.1 12302 15.5 <.001
Diabetes 4853 22.6 15049 19.0 <.001
Diabetes with chronic complications 1462 6.8 4589 5.8 <.001
Hemiplegia or paraplegia 416 1.9 1609 2.0 0.408
Renal disease 1833 8.5 5734 7.2 <.001
Moderate or severe liver disease 94 0.4 298 0.4 0.191
selective COX-2 inhibitors
No 18872 87.9 69896 88.1 0.504
Yes 2588 12.1 9435 11.9
Average (±sd) DDD 78.0 (±151.1) 85.5 (±231.7) 0.014b
tNSAID
No 2014 9.4 8517 10.7 <.001
Yes 19446 90.6 70814 89.3
Average (±sd) DDD 87.2 (±145.8) 94.5 (±170.0) 0.001b
preferential COX-2 inhibitors
No 15681 73.1 57451 72.4 0.058
Yes 5779 26.9 21880 27.6
Average (±sd) DDD 61.6 (±121.9) 62.2 (144.6) 0.278b
a: weighted according to the matched sizes of cases.
b: Two-sample t-tests were conducted at the natural logarithm of average DDD.
DDD: define daily dose; NT: new taiwan dollar; sd: standard deviation; tNSAID: traditional NSAID.
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separate conditional logistic regressions with MPR of se-
lective COX-2 inhibitors as a continuous independent
variable together with covariates (Table 2). The analyses
were conducted in the total subject group and also sub-
groups of age (age>=65, age<65) and gender (males,females). It was estimated that for people taking selective
COX-2 inhibitors for the whole 5 years prior to the
index date the OR was 0.51 (95% CI=0.29~0.90,
p=0.021) for developing CRC, and the OR was smaller
(0.36, 95% CI=0.08~1.67, p=0.193) in people aged less
than 65, and was larger (0.57, 95% CI=0.31~1.07,










value# with at least 1
prescription
# of nonusers # with at lease 1
prescription
# of nonusers
all subjects aged 18-100 years old
5 years 2588 18872 9435 69896 0.51 (0.29, 0.90) 0.021
3 years 2393 25117 8293 90607 0.58 (0.39, 0.86) 0.007
1year 1264 31959 4153 121708 0.60 (0.46, 0.80) <.001
6 months 822 35401 2619 123242 0.72 (0.56, 0.93) 0.012
3 months 533 35690 1652 124209 0.80 (0.64, 1.01) 0.056
subjects with aged 65-100 years old
5 years 2243 10145 8242 37553 0.57 (0.31, 1.07) 0.079
3 years 2073 13600 7247 49098 0.63 (0.41, 0.97) 0.035
1year 1092 19000 3630 66182 0.64 (0.48, 0.88) 0.005
6 months 706 19386 2282 67530 0.72 (0.55, 0.95) 0.021
3 months 461 19631 1450 68362 0.83 (0.65, 1.07) 0.147
subjects with aged 18-64 years old
5 years 345 8727 1193 32344 0.36 (0.08, 1.67) 0.193
3 years 320 11517 1046 41508 0.45 (0.15, 1.34) 0.152
1year 172 15959 524 55525 0.53 (0.25, 1.11) 0.090
6 months 116 16015 336 55713 0.82 (0.46, 1.48) 0.520
3 months 72 16059 201 55848 0.73 (0.43, 1.26) 0.262
male subjects
5 years 1185 11697 4175 43446 0.48 (0.19, 1.24) 0.131
3 years 1085 15145 3673 54675 0.57 (0.30, 1.08) 0.085
1year 563 20298 1799 70685 0.59 (0.38, 1.91) 0.016
6 months 366 20495 1095 71389 0.70 (0.47, 1.05) 0.087
3 months 237 20624 660 71824 0.80 (0.56, 1.13) 0.203
female subjects
5 years 1403 7175 5260 26450 0.52 (0.25, 1.08) 0.080
3 years 1308 9972 4621 35931 0.59 (0.35, 0.98) 0.042
1year 701 14661 2354 51023 0.61 (0.42, 0.89) 0.009
6 months 456 14906 1523 51854 0.73 (0.52, 1.01) 0.056
3 months 296 15066 992 52385 0.80 (0.60, 1.07) 0.136
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parison of estimated ORs between males and females
was similar (males: OR=0.48, 95% CI=0.19~1.24,
p=0.131; females: OR=0.52, 95% CI=0.25~1.08, p=0.080).
When considering different duration of selective
COX-2 inhibitor usages prior to the index date, the ORs
increased from 0.51 (95% CI=0.29~0.90, p=0.021) of 5
year-usage to 0.80 (95% CI=0.64~1.01, p=0.056) of 3
month-usage. Significant differences appeared with the
6-month, 1-year, 3-year and 5-year usages. For the older
age group (age>=65 years old), the ORs increased from
0.57 (95% CI=0.31~1.07, p=0.079) for 5 year-usage to
0.83 (95% CI=0.65~1.07, p=0.147) for 3 month-usage.
Only the usages of 3-years, 1-year and 6-months were
shown to be statistically significant. Although the
younger age group (aged 18–64) had smaller ORs from0.36 (95% CI=0.08~1.67, p=0.193) for 5 year-usage to
0.73 (95% CI=0.43~1.26, p=0.262) for 3 month-usage,
none of these estimated effects were significant. The
comparison of estimated ORs between males and
females was also similar. Significant drug usage effects
were found at 1-year usage by males (OR=0.59, 95%
CI=0.38~0.91, p=0.016) and at 3-year and 1-year usage
by females (3-year: OR=0.59, 95% CI=0.35~0.98,
p=0.042; 1-year: OR=0.61, 95% CI=0.42~0.89, p=0.009).
To investigate the risk reduction at various MPRs of
drug usage for prior durations, the estimated ORs were
computed by using indicator variables for at least 10% to
90% (in 10% intervals) of MPRs at follow-up durations
in 9 separate conditional logistic regressions with “no
use” as the reference category. These estimated ORs
with standard error of parameter estimate less than 0.45
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Figure 2. The risk reduction curves, which consist of
ORs, decrease as the MPRs increase, and all of the esti-
mated ORs show protection effects (ORs<1). ORs show-
ing significant protection effects are at 10% and 20% of
5-year cumulative usage, at 10% to 40% of 3-year usage,
at 10% to 80% of 1-year usage, and at 30% to 60% and
80% of 6-month usage. Except for the 3-month curve,
the other 4 curves (5-year, 3-year, 1-year and 6-month)
are closer together. Figure 3 shows plots for subgroups
of age (age>=65 and age<65) and gender (males and
females). The ORs for the least 10% of usage were more
heterogeneous in people with age less than 65 and in
males.
For the sensitivity analyses (Table 3), using the 5-year
follow-up group for the 3-year and 1-year analyses
reveals similar estimates only with less statistical signifi-
cance. When considering participants without any prior
history of cardiovascular events, the estimated ORs are
not very different.
Discussion
Potential chemopreventive benefits were investigated
using a database of cancer patients, and a large database
of Taiwanese patients. We were able to demonstrate a
dose–response protective effect for selective COX-2
inhibitors, which was related to the occurrence of CRC
in individuals.
Based on our results, the proportion of people pre-
scribed at least one COX-2 inhibitor was not significantlyMedication poss
















Figure 2 Odds ratios for developing colorectal cancer in different MP
10% and 20% of 5-year cumulative usage, at 10% to 40% of 3-year usage, a
6-month usage).different (p = 0.595) between CRC patients and the con-
trol group. Usage of selective COX-2 inhibitors between
the 2 groups was only different for cumulative DDD. This
suggested a potential dose–response relationship for risk
reduction. Significant reduction in risk regarding CRC
was found for those taking selective COX-2 inhibitors
over 6 months (28%, OR = 0.72), 1 year (40%, OR = 0.60),
3 years (42%, OR = 0.58) and 5 years (49%, OR = 0.51). In
the group with subjects aged 65 or younger, there was a
more pronounced reduction in risk (63% following 5 years
of use), however there was no statistical significance.
Risk reduction was similar between males and females,
and could even be observed at MPRs as low as 10%. In
terms of various MPRs (Figure 2), except for the 3-month
curve, the other 4 curves (5-year, 3-year, 1-year and
6-month) are closer together. Given that all of the MPRs
from 3-month were all not statistically significant,
these results might suggest a potential minimum treat-
ment period for chemopreventive effects. In addition, a
U-shaped curve can be observed from female patients
indicated the protection effects were not associated with
increased MPRs. Future studies may look into the dis-
appearance of protection trend by identifying common
diseases requiring long-term medication treatment in
females.
COX-2 has been found to be over-expressed in many
cancers, including CRC [3]. Blockade of COX-2 would
down-regulate its metabolic product, PGE2, thereby de-
creasing the risk of CRC [3]. Prostaglandin levels correl-
ate with disease activity and are consequently correlatedession ratio (MPR)
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b. Patients aged less than 65 years old




























5 years 3 years 1 year 6 months 3 months 
Figure 3 Odds ratios for developing colorectal cancer in different MPRs for selective COX-2 inhibitors in (a) age>=65, (b) age<65,
(c) males and (d) females (Note: Significant odds ratios are at (a) 10% of 5-year, 10% to 40% of 3-year, 10% to 50% of 1-year, 30% to
60% of 6-month, and 90% of 3-month; (d) 10% of 5-year, 20% to 40% of 3-year, 10% to 50% of 1-year, 40% of 6-month).
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Prostaglandins derived from COX-1 and COX-2 appear
to play a protective role. Theoretically, NSAIDs and
COX-2 inhibitors should be capable of inhibiting intes-
tinal production of prostaglandins involved in tissuerepair processes. However, previous research has
demonstrated conflicting data in animal and clinical
studies [3].
Patients administered celecoxib show reduction in size
and number of adenomas [1]. Bertagnolli et al. [12]
Table 3 Sensitivity analyses














5-year follow-up prior to index date
main analysis: maximum numbers of participants in different
years of follow-up
2588 18872 9435 69896 0.51 (0.29, 0.90) 0.021
using the same 5-year follow-up group for 3- year and 1-year
analyses
2588 18872 9435 69896 0.51 (0.29, 0.90) 0.021
participants without any occurance of myocardial infarction
or congestive heart failure
2048 17238 7584 64687 0.57 (0.30, 1.08) 0.085
patients without any occurance of peptic ulcer disease 1112 12374 4597 52859 0.61 (0.19, 1.97) 0.412
patients with any occurance of peptic ulcer disease 1476 6498 4838 17037 0.31 (0.08, 1.19) 0.089
patients without any occurance of colon or rectal polyps 2520 18447 9432 69895 0.55 (0.30, 1.98) 0.044
3-year follow-up prior to index date
main analysis: maximum numbers of participants in different
years of follow-up
2393 25117 8293 90607 0.58 (0.39, 1.86) 0.007
using the same 5-year follow-up group for 3- year analysis 2376 19084 8489 70842 0.60 (0.40, 0.89) 0.011
participants without any occurance of myocardial infarction
or congestive heart failure
1990 23458 7001 85573 0.61 (0.39, 0.94) 0.026
patients without any occurance of peptic ulcer disease 1190 17857 4737 74165 0.71 (0.37, 1.36) 0.304
patients with any occurance of peptic ulcer disease 1203 7260 3556 16442 0.49 (0.20, 1.20) 0.117
patients without any occurance of colon or rectal polyps 2316 18671 8488 70841 0.61 (0.40, 0.91) 0.016
1-year follow-up prior to index date
main analysis: maximum numbers of participants in different
years of follow-up
1264 31959 4153 121708 0.60 (0.46, 0.80) <.001
using the same 5-year follow-up group for 3-year and 1-year
analyses
1247 20213 4380 74951 0.61 (0.46, 0.81) 0.001
participants without any occurance of myocardial infarction
or congestive heart failure
1139 33696 3807 118187 0.59 (0.43, 0.79) 0.001
patients without any occurance of peptic ulcer disease 765 28501 2951 111326 0.79 (0.54, 1.15) 0.227
patients with any occurance of peptic ulcer disease 499 3458 1202 10382 0.56 (0.17, 1.85) 0.340
patients without any occurance of colon or rectal polyps 1216 19797 4379 74951 0.61 (0.46, 0.81) 0.001
6-month follow-up prior to index date
main analysis: maximum numbers of participants in different
years of follow-up
822 35401 2619 123242 0.72 (0.56, 0.93) 0.012
using the same 5-year follow-up group for 3- year and 1-year
analyses
806 20654 2747 76584 0.72 (0.56, 0.93) 0.013
participants without any occurance of myocardial infarction
or congestive heart failure
744 34091 2411 119583 0.70 (0.53, 0.91) 0.009
patients without any occurance of peptic ulcer disease 491 28775 1855 112422 0.95 (0.68, 1.33) 0.777
patients with any occurance of peptic ulcer disease 331 6626 764 10820 0.67 (0.24, 1.88) 0.443
patients without any occurance of colon or rectal polyps 786 20227 2747 76583 0.71 (0.55, 0.92) 0.009
3-month follow-up prior to index date
main analysis: maximum numbers of participants in different
years of follow-up
533 35690 1652 124209 0.80 (0.64, 1.01) 0.056
using the same 5-year follow-up group for 3-year and 1-year
analyses
521 20939 1721 77610 0.80 (0.64, 1.01) 0.057
participants without any occurance of myocardial infarction
or congestive heart failure
480 34355 1502 120492 0.78 (0.61, 0.98) 0.036
patients with any occurance of peptic ulcer disease 209 6748 511 11073 0.76 (0.31, 1.85) 0.550
patients without any occurance of colon or rectal polyps 507 20506 1721 77609 0.79 (0.63, 0.99) 0.038
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reported that the risk of developing one or more aden-
omas in 3 years was reduced by 33% in patients treated
with 200 mg of celecoxib. Risk was reduced by 45% in
patients given 400mg of celecoxib as compared with the
placebo group. The Prevention of Colorectal Sporadic
Adenomatous Polyps (PreSAP) trial [13] studied similar
patients, and showed a 36% reduction in adenoma recur-
rence and 51% reduction in advanced adenoma in
patients taking 400 mg of celecoxib once a day. A meta-
analysis [7] of the two clinical trials [12,13] showed a
44% reduction in the recurrence of any adenoma, and a
55% reduction in advanced adenoma during 3 years of
follow-up. For rofecoxib, the Adenomatous Polyp Pre-
vention on Vioxx (APPROVe) trial [14] identified that
adenoma recurrence was less frequent (RR = 0.76) in the
rofecoxib group. Chemopreventive effects were more
pronounced in the first year (RR=0.65) than in the sub-
sequent two years (RR=0.81) [3]. From that study, the 3-
year risk reduction was estimated at 42% (OR = 0.58,
95% CI = 0.39~0.86), indicating a similar protective ef-
fect regardless of CRC occurrence. The median ages of
subjects in the two celecoxib studies were 61 [13] and
59 [12] years. In our study, we observed a 55% risk re-
duction in people younger 65, decreasing further to 37%
for those 65 and older.
To date, no reports have been published investigating
the chemopreventive roles of non-aspirin NSAIDs, espe-
cially selective COX-2 inhibitors, in general populations
[7]. An earlier study [15] investigating the effects of as-
pirin and other NSAIDs on risk reduction revealed an
OR of 0.76 (95% CI = 0.58~1.00) for colon cancer, and
0.75 (95% CI = 0.49~1.14) for a 3-year follow-up with at
least seven prescriptions.
Selective COX-2 inhibitors are associated with
increased risk of cardiovascular events [7,16]. The with-
drawal of rofecoxib [14], along with the early termin-
ation of the Bertagnolli [12] and Arber [13] studies were
all because of more serious adverse cardiovascular ad-
verse events. Selective COX-2 inhibitors have also been
associated with gastrointestinal symptoms, primarily as a
result of the inhibition of mucosal protective prostaglan-
dins [3,4,16]. The prevalence of gastrointestinal events
was greater in the celecoxib groups of the Arber Study.
Additionally, renal disease or hypertension was signifi-
cantly higher in the celecoxib group of the Arber study,
and also in one of the two celecoxib groups of the
Bertagnolli study [7]. In our study, we did not include
adverse events as outcomes. During follow-up, we found
that overall, there was a greater number of cancer
patients using COX-2 inhibitors, however the average
number was lower than those seen for the control group.
This is possibly because of adverse events, therefore ad-
ministration of medication has to be discontinued. Weinvestigated patients without any occurrence of myocar-
dial infarction or congestive heart failure and peptic
ulcer disease. It was found that the estimates of risk re-
duction were not largely different in patients without
cardiovascular events. Therefore, the occurrence of car-
diovascular events might not have effect on the associ-
ation of COX-2 inhibitors and CRC. In terms of peptic
ulcer disease, greater increases in the risk reduction
were observed in patients with occurrence of peptic
ulcer disease. However, in this study we did not have
enough sample size to provide sufficient statistical
evidence.
We have included both refecoxib and celecoxib in the
analysis. Since rofecoxib was withdrawn in 2004, the
study results may not directly reflect the effect of the
current available COX-2 inhibitor (celecoxib).
The ICD-9 codes of 140–208 are sometimes provided
by the Taiwan NHI program for cancer-screening pur-
poses. The result of this is that the incidences of cancer
can be greatly overestimated. In our study, CRC patients
were identified by linking their encrypted personal iden-
tification number to the Registry for Catastrophic Illness
patients with ICD9 code 153–154. For patients to be in
the Registry for Catastrophic Illness, their medical
records need to be reviewed so that they can qualify
for 100% reimbursement of disease-related medical ex-
penses. Our database comprised approximately 90% of
the Taiwan cancer incidence registry. A possible reason
why patients might not appear in the catastrophic illness
registry of the NHI program may include short period
between diagnosis of CRC and death. These identified
patients were excluded from the study. Therefore, we
believe that 90% of CRC patients in the Catastrophic Ill-
ness Registry was a reasonable representation of CRC
patients in Taiwan.
Our study also has limitations on some key confoun-
ders of CRC, including familial adenomatous polyposis
[17], calcium [18], folate, methionine and alcohol intake
[19] as well as exercise, obesity and smoking habit [7].
These factors were not recorded in the NHI database,
and might reduce the estimates of risk reduction, if they
were included in regression analyses. For a given partici-
pant, the usage of selective COX-2 inhibitors might have
been affected by co-prescriptions of other NSAIDs. To
adjust for this situation, the conditional logistic regres-
sions were also conducted with two MPR covariates for
tNSAIDs and preferential COX-2.
The database used did not include information for
over-the-counter use. Hence, some underestimation of
the NSAIDs used may have occurred. Because the Tai-
wan NHI program provides comprehensive medication
coverage, any drug use not recorded in the database
would be limited to short-term relief of symptoms, and
the effect on the study results is therefore limited.
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enoma into CRC may take as long as 10–15 years [7].
Given that outcomes can only be assessed by colonos-
copy, there may be some false negatives in the control
group. The control group included people without CRC
or other cancers before and after the index dates. This
was to prevent possible misclassification due to late
diagnosis of cancers. In the sensitivity analysis, we also
investigated patients without any occurrence of colon
and rectal polyps. It was found that the estimates of risk
reduction were not largely different from the main ana-
lysis. Therefore, the effect on the association of COX-2
inhibitors and CRC might be limited.
Conclusion
Few studies have focused on the chemopreventive effects
of selective COX-2 inhibitors on CRC in the general
population. The results support the chemopreventive
role of selective COX-2 inhibitors in CRC. Risk reduc-
tion occurred after 6 months, 3 years and 5 years of con-
tinual use of the drugs. Additionally, the frequencies of
use for COX-2 inhibitors from 1–5 years may be as low
as 10% of MPRs to achieve at least 10% risk reduction
with respect to developing CRC. Given limited reports
from individuals with no increased risk of CRC, our
results provide information in the general population.
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